Health Related Quality of Life (HRQoL) among Breast Cancer Patients Receiving Chemotherapy in Hospital Melaka: Single Centre Experience

Dang Chee Chean*, Wong Kuo Zang, Michelle Lim, Nooraziah Zulkifle

Abstract

Objective: To investigate the impact of chemotherapy on quality of life (QoL) among breast cancer patients and to evaluate the relationship with age, cancer stage and presence of any comorbidity. Methods: A prospective study was conducted among breast cancer patients receiving chemotherapy in Hospital Melaka from 1st January 2014 to 31st July 2014. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) was given to patients to fill in prior chemotherapy (baseline) and after the third cycle of chemotherapy. Socio-demographic and clinical data were collected and analyzed using SPSS version 20. Result: Respondents were 32 female patients [mean age (SD): 49.7(9.93) years]. They reported a significant lower global health status (P < 0.01) and significant higher symptoms of nausea and vomiting (P < 0.01), loss of appetite (P = 0.028) and diarrhea (P = 0.026) after the third cycle of chemotherapy as compared to baseline. Compare to, this study showed significant better emotional functioning (P < 0.01) and social functioning (P < 0.01) than the EORTC QLQ-C30 Reference Values 2008 for breast cancer cases. Under symptom scales higher scores were noted for appetite loss (P = 0.017), nausea and vomiting (P < 0.01). Age, stage and comorbidity had no clear associations with global health status in our patients (P > 0.05). Conclusion: Chemotherapy did reduce the QoL of breast cancer patients. Management of chemotherapy-induced loss of appetite, diarrhea, nausea and vomiting should be improved for a better outcome.

Keywords: Breast cancer- chemotherapy- quality of life (QoL)- EORTC QLQ-C30
Materials and Methods

Sample and Procedure

This was a cross-sectional, descriptive study of the health-related quality of life among breast cancer patients treated with chemotherapy which was conducted at Hospital Melaka from January 2014 to July 2014. Conventional sampling was used as sampling method. Besides, this study was registered under National Medical Research Register (NMRR) (NMRR-14-335-19480) and permission to conduct this study was obtained from the Ministry of Health (MOH) Research and Ethics Committee (MREC), Malaysia.

The inclusion criteria included respondents that were diagnosed with breast cancer and enrolled in Hospital Melaka to receive FEC regimen (5-Fluorouracil, Epirubicin, Cyclophosphamide) as chemotherapy treatment. Besides, the respondent should be 18 years old and above who was agreed to participate with written consent and could either communicate in English, Malay or Chinese language and understood the study procedure. Those patients with inability to give full cooperation due to severity of the illness will be excluded in this study.

An assessment instrument in form of questionnaires were given to respondents to fill in before initiation of the first cycle chemotherapy, and again after the third cycle of chemotherapy. Informed consent to participate in the study was obtained from patients prior to the guided, face to face interview. The subject demographic and medical information to ensure validity of diagnosis, stages of breast cancer and treatment were obtained from medical records. The data was collected personally by the researcher and time to complete the questionnaire was approximately 15-30 minutes.

Assessment Instrument

The health-related quality of life of respondents were measured using Malay, English or Chinese version of EORTC QLQ-C30. These questionnaires were copyright instruments and permission to use them was obtained from the EORTC Quality of Life Study Group in Brussels, Belgium. The validity and reliability of the EORTC QLQ-C30 in measuring the HRQoL of cancer patients in multi-cultural clinical research settings have been reported by Aaronson and colleagues (1993). The translated Malay and Chinese version was validated and have well documented psychometric properties (Yusoff et al., 2010; Magaji et al., 2012). In EORTC-QLQ C-30, there are 30 questions that assess three main domains which are global health status, functional status, symptoms and financial status. A raw score of the participants’ responses were transformed according to EORTC scoring manual (Fayers et al., 2001). The score ranges from zero to 100, with higher score representing better quality of life for the functioning and global quality of life but representing poorer quality of life if higher level of symptoms.

Results

Patients’ Demographic

A total of 32 respondents were participated in the study. All respondents were female. Majority of the patients were from age group between 40 to 60 years old (65.6%, n=21). They were more Malays (78.1%, n=25) followed by Chinese (18.8%, n=6) and Indian (3.1%, n=1). Almost all respondents were married (93.8%, n=30) and more than half respondents have 3 or less children (62.5%, n=20).

In term of education level, more than half (53.1%, n=17) were reported to have secondary school level of education, followed by primary school (25%, n=8) and tertiary school (18.8%, n=6) and unemployment (56.3%, n=18) and were housewife. Other respondents were working (31.2%, n=10), retired (9.4%, n=3) and self-employed (3.1%, n=1). Most respondents had a household income ranging from RM1001 to RM3000 per month (53.1%, n=17) followed by income ranging from RM0 to RM 1000 (28.1%, n=9). 18 of the respondents live in rural areas (56.3%) while others reside in urban. About 47% of respondent came with breast cancer at early stage and the remaining respondents were diagnosed late stage of breast cancer with 46.8% Stage III and 6.3% Stage IV respectively. About 81% of the respondents underwent surgery (n=26) either lumpectomy or mastectomy and majority of them had comorbidity (53.1%, n=17). Details on socio-demographic information are presented in Table 1.

Health-related quality of life and global health status

Table 2 presents the health-related quality of life before and after chemotherapy as well as patient’s global quality of life and patient’s functioning as compared to reference value for all cancer patients provided by EORTC Quality
Comparison of global health status score, functional scale score and symptoms scale/item score before and after chemotherapy indicated that breast cancer patient who received chemotherapy showed a significant lower degree of global health status \((p=0.001)\), significant increase of certain symptoms of chemotherapy side effects which are nausea and vomiting \((p=0.000)\), appetite loss \((p=0.028)\), and diarrhea \((p=0.026)\). There were no significant between before and after chemotherapy in term of functional scale.

Global health status score was same with reference group. Under functional scales, physical functioning and role functioning were lower than reference value whereas emotional, cognitive and social functioning of this study were higher than reference value. For symptoms scales, nausea, vomiting and appetite loss were found to be higher than reference value while other symptoms scale except insomnia showed similar result with reference value. For insomnia symptom, it was lower than reference value. Breast cancer staging had no significant correlation with global health status patient underwent chemotherapy \((p=0.22)\). In addition, there were no significant relationship found between comorbidity and global health status \((p=0.872)\) (Table 3). Age patient was not significantly correlated with global health status of patient receive chemotherapy as well \((r = -0.194, p=0.286)\).

**Discussion**

The results of this study demonstrated that patients who were currently receiving chemotherapy had significantly lower global health status. Symptoms such as nausea, vomiting, loss of appetite and diarrhea are significantly higher after the chemotherapy. In parallel with our findings, a study done by Watters (2003) on 65 women with breast cancer receiving anthracycline-based adjuvant chemotherapy using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-Module (QLQ-C30) determined that patients had a decrease in global health status after adjuvant chemotherapy compared to patients’ baseline status before chemotherapy. According to the comments leaved by patients in study done by Palmer (1980) on what extent the chemotherapy affect quality of life, some stated that “treatment was unbearable” or “never again” and some stated that the experience had been “most unpleasant” or they had “dreaded” the treatment “but would have it again if it were recommended for their health’s sake.” This showed that they experienced poor quality of life following chemotherapy.

Chemotherapy-induced nausea and vomiting have been commonly rated as the most unpleasant and distressing side effect (Cohen et al., 2007). Consistent with a previous study done by Lua (2012) that involving larger number of patients \((n=41)\), there is a significant proportion of patients remain to suffer nausea and vomiting after receiving chemotherapy even after usual antiemetics management. In that study, patients who experienced vomiting exhibited lower quality of life than those who did not suggesting possible close association between the occurrence of vomiting and quality of life. Besides, in a
A study done by Gozzo and colleagues (2013) by using EORTC QLQ-C30 on 79 women receiving chemotherapy revealed that 93% had nausea and 87% had vomited at least once during the treatment. Cytotoxic drugs used by the participants in this study may become the reason of statistically significant higher nausea and vomiting after chemotherapy as cyclophosphamide and epirubicin present an emetic potential of level 4 which has higher risk (>90%) to cause emesis (MOH, Malaysia, 2011).

Diarrhea is one of the most common chemotherapy side effects and different mechanisms may be involved in its pathogenesis (Sharma et al., 2005; Melicher and Zezulova, 2011). Cytotoxic drugs impair the turnover of intestinal epithelia and induce flattening of the villi and an increased exposure of luminal contents to crypts (Keefe et al., 2000). These alterations could be involved in the frequent recurrence of diarrhea in patients undergoing chemotherapy (Kadowaki and Yamaguchi, 2011). In this study, it was found that there is a significant increase in diarrhea in patients after undergoing chemotherapy. This finding is parallel to the study result done by Russo (2013). From their study result, it could be supposed that in patients with extra GI neoplasms, such as breast cancer, the FEC regimen induces alteration in the intestinal permeability, which was associated with modifications in the levels of hormones regulating the growth and physiology of intestinal membranes that resulted in diarrhea. In fact, Palmer (1980) reported patient who had received the single or multiple chemotherapy regimen complained of diarrhea which occurred within 12 hours after starting the treatment and most of them experienced reduction of appetite which is in line with our study.

The effect of chemotherapy on functional status of breast cancer patients is not significant in this study. This may due to adequate pain and symptoms management, achieving a sense of control and strengthening relationship with family member (Singer et al., 1999). Although the results found in this study point to a stable functional status during chemotherapy, most of the published studies evidence a significantly negative interference of the chemotherapy in the functional status of women with breast cancer. Watters (2003) reported moderate decline in physical function by patients receiving chemotherapy in

Table 2. Comparison Health Related Quality of Life Pre-Chemotherapy, Post-Chemotherapy and European Organisation for the Research and Treatment of Cancer (EORTC) QLQ C-30 Reference Values 2008

| Constructed scales | Pre Global Health Status | Post Global Health Status | Z statistic a | *P value | EORTC QLQ-C30 References Values 2008 |
|--------------------|--------------------------|--------------------------|--------------|----------|--------------------------------------|
|                    | Median (IQR)             | Median (IQR)             |              |          | Median (IQR)                         |
| Global Health Status| 75 (22.9)                | 66.7 (8.3)               | -3.2         | 0.001    | 66.7 (50.0-83.3)                     |

Function scale

| Physical Functioning | 93.3 (23.3) | 80.0 (20.0) | -1.6 | 0.11 | 86.7 (66.7-93.3) |
| Role Functioning     | 100.0 (16.7) | 75.0 (33.3) | -1.8 | 0.076 | 83.3 (50.0-100.0) |
| Emotional Functioning| 83.3 (33.3) | 91.7 (33.3) | -0.9 | 0.342 | 75.0 (50.0-83.3) |
| Cognitive Functioning| 100.0 (33.3) | 100.0 (33.3) | -0.6 | 0.526 | 83.3 (66.7-100.0) |
| Social Functioning   | 100.0 (16.7) | 100.0 (12.5) | -0.2 | 0.823 | 83.3 (66.7-100.0) |

Symptoms scale/ items

| Fatigue             | 27.8 (33.3) | 33.3 (33.3) | -1.6 | 0.105 | 33.3 (11.1-44.4) |
| Nausea & Vomiting   | 0.0 (0.0)   | 33.3 (50.0) | -3.7 | 0.0    | 0.0 (0.0-0.0)    |
| Pain                | 16.7 (33.3) | 16.7 (33.3) | -0.7 | 0.459 | 16.7 (0.0-50.0)  |
| Dyspnea             | 0.0 (0.0)   | 0.0 (0.0)   | -0.9 | 0.334 | 0.0 (0.0-33.3)   |
| Insomnia            | 0.0 (33.3)  | 0 (33.3)    | -1.3 | 0.196 | 33.0 (0.0-33.3)  |
| Appetite Loss       | 0.0 (33.3)  | 33.3 (66.7) | -2.2 | 0.028 | 0.0 (0.0-33.3)   |
| Constipation        | 0.0 (25.0)  | 0 (33.3)    | -0.9 | 0.357 | 0.0 (0.0-33.3)   |
| Diarrhea            | 0.0 (0.0)   | 0.0 (0.0)   | -2.2 | 0.026 | 0.0 (0.0-0.0)    |
| Financial Difficulty| 0.0 (33.3)  | 0.0 (33.3)  | -0.4 | 0.67  | 0.0 (0.0-33.3)   |

* Wilcoxon test, P value < 0.05

Table 3. Relationship of Comorbidity and Cancer Staging with Global Health Status Post Chemotherapy

| Measures | Global Health Status post chemotherapy | Mean differenceb (95% confidence Interval) | P value† |
|----------|----------------------------------------|------------------------------------------|----------|
| Comorbidity |                                           |                                           |          |
| Without comorbidity | 68.9 (13.9) | -0.9(-12.3, 10.5) | 0.872    |
| With comorbidity   | 64.8(13.8) |                                           |          |
| Staging            |                                           |                                           |          |
| Stage I and II cancer | 68.9 (13.9) | 6.8(-4.3, 18.0) | 0.22     |
| Stage III and IV cancer | 62.1 (16.6) |                                           |          |

† Independent t-test, P value < 0.05
their study. Emotional and social function had improved by the completion of chemotherapy and there was no significant change in role and cognitive function from baseline to completion of therapy. Other than that, this study was in contrast with a study which stated that the worsening physical and psychological function of women with breast cancer was associated with chemotherapy (Ogte and Ozkan, 2008). The differences may be due to different patients’ population (sample size or patient age).

A comparison between the quality of life of breast cancer patients in Hospital Melaka and general population by using EORTC QLQ-C30 reference value 2008 was also carried out in the current study. The reference data is important to provide information about the distribution of quality of life scores for specific cancer populations with certain characteristics to explain differences in clinical outcomes. They provide one potential reference point against which future populations may be compared (Scott et al., 2008). In this comparison, the patients in Hospital Melaka presented with higher event of appetite loss, nausea and vomiting symptoms compare with the reference value based on the result obtained. The difference in result can be due to the sample population difference, as reference data was collected from different countries in the world which include non-Asian country, while sample of this study is only obtained from Malaysian. In another study, Bourdeau and colleagues (2012) revealed that ethnicity influences nausea and vomiting in patient receiving chemotherapy. The sample of that study consisted of Caucasians, Hispanics, Asians, and African Americans. In parallel to the current study, the published results indicate that Asian women with breast cancer undergoing anthracycline-based chemotherapy experienced statistically significantly more clinically important nausea and vomiting than non-Asian counterparts.

It was postulated that older women with breast cancer would experience declines in global health status during chemotherapy compare to younger women. The postulation is based on the fact that body composition tends to change in a predictable manner during adult life for example, age-related differences in muscle fibre types, numbers of functioning motor units and changes in muscle energetic with the most substantial decline in muscle mass of as much as 40 to 50% by the eight decade of life relative to young adulthood (Cohn et al., 1980; Kallman et al., 1990). In spite of the postulation, this study found that there was no correlation between age and quality of life. This finding is in agreement to Watters (2003), who reported quality of life of young (<65 years old) and older (≥65 years old) patients similar decline in global health status. Similar results also have been reported by Mols (2005) which concluded that age is not a predictor of quality of life. On contrary, Akin and co-workers reported a study that showed relationship between quality of life and age. In that study, the overall quality of life and its dimension (emotional wellness, functional wellness and additional concerns) were more negatively affected in younger patients (Akin et al., 2008). However, the age range of patients in this study are not normally distributed which may contribute to the different result obtained in comparison to Watters (2003) and Mols (2005).

Interestingly, the current study shows no correlation between extend of disease and quality of life. Similar results have been reported by Dehkordi (2009), that quality of life was not affected by stage of cancer. In contrast, Rustoen (1995) and Holzner (2001) in two separate studies found that the extent to which quality of life of cancer patients depends on the time elapsed since initial treatment; with an increase in extent of disease, a decrease in the quality of life was observed. The difference may be due to different in cancer types in each study. Also, uneven distribution of patients in each tumor stages in the current study that may cause differences in study result. Similar deduction is obtained for comorbid condition whereby no significant correlation was found between comorbid condition and quality of life of the patient. Influence of a given comorbid condition will vary depending on where a patient is located within the cancer care trajectory. According to a study done by Wolf (2005), patients with comorbidity such as diabetes mellitus did not appear to worsen breast-cancer specific outcome which was in line with this study result. However, Mao (2007) observed that symptom burden among cancer survivors in their study is substantial and impacted by other comorbidities.

In conclusion, this study showed chemotherapy increase in nausea, vomiting, diarrhea and loss of appetite as well as reducing global health status among breast cancer patients in Hospital Melaka. Although the quality of life among breast cancer patients is comparable with general population (from EORTC reference value), result showed that age, staging and comorbidity have no association with global health status in breast cancer patient. Deterioration in quality of life is caused by pain, insomnia, fatigue, physical difficulties, emotional, and cognitive distress. From this study, we can see that symptoms presented before chemotherapy may be an important variable in finding risk factors for the development of the symptoms over the course of treatment (Ogte and Ozkan, 2008). Royer (2009) noticed that women do not communicate with their healthcare providers about symptoms. Thus, results from this study may be useful for pharmacist so that pharmacist interventions related to symptom management can be carry out to assist women in understanding the possible cause of symptoms, which may lead to more effective coping with their symptoms. The incidence of chemotherapy induced-nausea and vomiting among this sample population indicate that there is still room for improvement towards better control of nausea and vomiting, perhaps through the introduction of complementary medicine or combination of antiemetic medication. Other than that, planned education programs addressing patients’ needs, help patients by providing verbal encouragement and introducing patients to positive role are crucial towards improving quality of life among breast cancer patients.

Acknowledgement

The authors would like to thank all the individuals who has directly or indirectly contributed to this study, especially to those participants who spent their time...
References

Aaronson NK, Ahmedzai S, Bergman B, et al (1993). The European organization for research and treatment of cancer qol-c30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 85, 365-76.

Akin S, Can G, Durna Z, Aydiner A (2008). The quality of life and self-efficacy of Turkish breast cancer patients undergoing chemotherapy. Eur J Oncol Nurs, 12, 449-56.

Bourdeau L, Frankel P, Yu W, et al (2012). Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy. J Support Oncol, 10, 149-54.

Cohen L, De Moor CA, Eisenberg P, et al (2007). Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings. Support Care Cancer, 15, 497-503.

Cohn SH, Vartsky D, Yasumura S, et al (1990). The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol, 45, 82-8.

Desalvo KB, Bloser N, Reynolds K, et al (2006). Mortality prediction with a single general self-rated health question: a meta-analysis. J Gen Intern Med, 21, 267-75.

Eisenbraun J, Scheer R, Kröz M, et al (2011). Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. Phytomedicine, 18, 151-7.

Fayers PM, Aaronson NK, Bjordal K, et al (2001). EORTCQLQ-C30 scoring manual, European organisation for research and treatment of cancer. Cancer Invest, 19, 573-80.

Gozzo T, Moyses A, Silva P, Almeida A (2013). Nausea, vomiting and quality of life in women with breast cancer receiving chemotherapy. Rev Gaúcha Enferm, 34, 110-6.

Helena M, Christina B, Bo N, Brandberg Y (2000). Health-related quality of life measured by the eortc qol-c30: reference values from a large sample of the Swedish population. Acta Oncologica, 39, 477-84.

Holzner B, Kemmler G, Kopp M, et al (2001). Quality of life in breast cancer patients-not enough attention for long-term survivors?. Psychosomatics, 42, 117-23.

Kadowaki S, Yamaguchi K (2011). Chemotherapy-induced stomatitis and diarrhea. Gan to kagaku ryoho.

Kallman D, Plato C, Tobin J (1999). The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol, 45, 82-8.

Keefe D, Brealey J, Goland G, Cummins A (2000). Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut, 47, 632-7.

Kumara NS, Mamat NM (2012). Health-related quality of life profile in relation to chemotherapy-induced nausea and vomiting among breast cancer patients. Asian J Psychiatr, 13, 131-6.

Luo L, Zakeri NS, Mamat NM (2012). Health-related quality of life among colorectal cancer patients in Malaysia: a study protocol. BMC Cancer, 12, 384.

Melicher B & Zezulova M (2011). The significance of altered gastrointestinal permeability in cancer patients. Curr opin support palliat care, 5, 47-54.

Mols F, Vingerhoets AJ, Coebergh JW, Van De Poll-Franse LV (2005). Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer, 41, 2613-9.

Montazeri A, Vahdaninia M, Harirchi I, et al (2008). Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up study. BMC Cancer, 8, 330.

Ogzce F, Ozkan S (2008). Changes in functional status and physical and psychological symptoms in women receiving chemotherapy for breast cancer. Asian Pac J Cancer Prev, 9, 449-52.

Pakhomov S, Jacobsen SJ, Chute CG, Roger VL (2008). Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care, 14, 530-9.

Palmer B, Walsh G, Mckinna J, Greening W (1980). Adjuvant chemotherapy for breast cancer: side effects and quality of life. BMJ, 281, 1594-7.

Royer HR, Phelan CH, Heidrich SM (2009). Older breast cancer survivors’ symptom beliefs. Oncol nurs forum, 36, 463-70.

Scott N, Fayers P, Aaronson N, et al (2008). EORTC-QLQ-C30 reference values (2008). European organization for research and treatment of cancer, Brussels, Belgium.

Sharma R, Tobin P, Clarke SJ (2005). Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol, 6, 93-102.

Singer P, Martin D, Kelner M (1999). Quality end-of-life care: patients’ perspectives. JAMA, 281, 163-8.

Watters JM, You JC, O’rourke K, et al (2003). Functional status is well maintained in older women during adjuvant chemotherapy for breast cancer. Ann Oncol, 14, 1744-1750.

Wolf I, Sandetzki S, Catane R, et al (2005). Diabetes mellitus and breast cancer. Lancet Oncol, 6, 103-11.

Yusoff N, Low W, Yip C (2010). The Malay version of the European organization for research and treatment of cancer quality of life questionnaire (eortc-qlq c30): reliability and validity study. Med J Malaysia, 9, 45-50.

Zainal AO, Nor Saleha IT (2011). The national cancer registry report. 2007. Ministry of health, Malaysia.